Empirical antifungal therapy in febrile neutropenic patients: Caution about composite end points and the perils of P values [5] (multiple letters)

Clinical Infectious Diseases

Volumn 39, Issue 11, 2004, Pages 1738-1739

  Powers, John H ^a   Wingard, John R ^b,c  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c Univ of Florida Shands Cancer Ctr ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CYTOTOXIC AGENT; FLUCONAZOLE; GROWTH FACTOR; VORICONAZOLE;

CANDIDA; CLINICAL TRIAL; DIAGNOSTIC TEST; DRUG FATALITY; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION PREVENTION; LETTER; MORTALITY; MYCOSIS; PATIENT SELECTION; PRIORITY JOURNAL; TREATMENT INDICATION;

ANTIFUNGAL AGENTS; FEVER; FUNGEMIA; HUMANS; NEUTROPENIA; STATISTICS;

EID: 9644291697     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/425922     Document Type: Letter

References (0)